Loading...
XLON
OXB
Market cap875mUSD
Dec 05, Last price  
619.00GBP
1D
0.00%
1Q
4.74%
Jan 2017
204.18%
Name

Oxford Biomedica PLC

Chart & Performance

D1W1MN
XLON:OXB chart
P/E
—
P/S
5.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.31%
Rev. gr., 5y
14.99%
Revenues
129m
+43.84%
824,000760,0007,219,00018,394,00019,120,00011,153,0007,718,0007,756,0005,375,00013,618,00015,909,00027,776,00037,590,00066,778,00064,060,00087,728,000142,797,000139,989,00089,539,000128,797,000
Net income
-43m
L-72.58%
-9,085,000-17,626,000-15,289,000-10,041,000-3,515,000-10,290,000-12,631,000-8,730,000-11,096,000-8,661,000-13,019,000-16,641,000-9,017,0007,541,000-16,066,000-6,245,00019,011,000-45,159,000-157,490,000-43,190,000
CFO
-51m
L+77.54%
-8,342,000-17,128,0004,730,000-18,133,0002,314,000-12,828,000-12,983,000-10,037,000-11,019,000-6,032,000-13,118,000-5,106,0002,979,00012,868,000-3,508,0003,116,00025,455,000-12,615,000-28,517,000-50,628,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
URL
https://www.oxb.com/
IPO date
Nov 15, 1996
Employees
894
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT